If a patient with streptococcal pharyngitis does not improve after 48 hours of azithromycin, what is an appropriate next step?

Study for APEA Management EENT Test with flashcards and multiple choice questions, each question has hints and explanations. Get ready for your exam!

Multiple Choice

If a patient with streptococcal pharyngitis does not improve after 48 hours of azithromycin, what is an appropriate next step?

Explanation:
When a patient with streptococcal pharyngitis does not improve after 48 hours on azithromycin, the next step is to switch to a penicillin-based therapy or a cephalosporin with beta-lactamase coverage. The reasoning is that Streptococcus pyogenes is typically susceptible to penicillin, so a beta-lactam antibiotic is likely to be effective even if a macrolide has failed due to resistance. Using a cephalosporin with beta-lactamase coverage also guards against possible co-infection with beta-lactamase–producing organisms, providing broader, more reliable bacterial eradication. Waiting longer or sticking with another macrolide would not address potential resistance, and doxycycline is not always appropriate as a first-line option for streptococcal pharyngitis due to safety and efficacy considerations in certain populations.

When a patient with streptococcal pharyngitis does not improve after 48 hours on azithromycin, the next step is to switch to a penicillin-based therapy or a cephalosporin with beta-lactamase coverage. The reasoning is that Streptococcus pyogenes is typically susceptible to penicillin, so a beta-lactam antibiotic is likely to be effective even if a macrolide has failed due to resistance. Using a cephalosporin with beta-lactamase coverage also guards against possible co-infection with beta-lactamase–producing organisms, providing broader, more reliable bacterial eradication. Waiting longer or sticking with another macrolide would not address potential resistance, and doxycycline is not always appropriate as a first-line option for streptococcal pharyngitis due to safety and efficacy considerations in certain populations.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy